ArticleAnnals of medicine2025
Global, regional, and national children and adolescent epilepsy burden, 1990-2021: an analysis based on the global burden of disease study 2021.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Bridging development and disease: the potential of LncRNAs as biomarkers and therapeutics in pediatric neurological disorders.Pediatric research · 2026Review
- Global, regional, and national burden and trends of idiopathic epilepsy among children and adolescents from 1990 to 2021: insights from the global burden of disease study 2021.Annals of medicine · 2025Article
- Regarding: 'Incidence, mortality, and DALYs of global pharyngeal cancer: systematic analysis and projections based on global burden of disease study 2021'.Annals of medicine · 2025Article
- Seizure Type Classification Based on Hybrid Feature Engineering and Mutual Information Analysis Using Electroencephalogram.Entropy (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpilepsy is a prevalent central nervous system disorder, affecting over 70 million people globally. It ranks fifth among neurological disorders in terms of disease burden. Epilepsy exhibits peak incidence in both childhood and older age, leading to a significant disease burden. This study aims to assess the burden of epilepsy in children and adolescents, analyze its key contributing factors, and identify strategies to mitigate the disease burden.
methodsThe disease burden of childhood and adolescent epilepsy was analyzed across spatial, temporal, and population levels using data from the Global Burden of Disease 2021 study.
resultsIn 2021, over 8 million children and adolescents worldwide were living with epilepsy. The disease burden in this population is greater in males than in females, with morbidity primarily concentrated in children under 5 years of age and mortality predominantly occurring in adolescents aged 15-19. The current disease burden is strongly correlated with population and epidemiological factors, and while incidence and prevalence are projected to rise, both mortality and Disability-Adjusted Life Years (DALYs) are expected to decrease.
conclusionThis study highlights the global changes in the disease burden of epilepsy in children and adolescents. Population factors have been identified as the primary drivers of the increasing burden, while improvements in public health policies and access to treatments have contributed to the decreasing burden. Despite the expected rise in the future incidence, targeted improvements in treatment accessibility and health budget allocations are essential to reduce the long-term burden of epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.